Trial Profile
A Phase IIa Open-Label Trial of AGEN1884 in Combination With Pembrolizumab in Subjects With Chemotherapy Naïve, PD-L1 High, Metastatic Non-Small Cell Lung Cancer (NSCLC)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Zalifrelimab (Primary) ; Pembrolizumab
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Agenus
- 21 Mar 2019 Status changed from recruiting to discontinued due to changes in the treatment landscape.
- 22 Aug 2017 Status changed from not yet recruiting to recruiting.
- 22 Jul 2017 New trial record